Kerry S. Campbell
Department of Cancer Research
Fox Chase Cancer Center
United States of America
Biography
Kerry S. Campbell Educational Background: Independent Member, Basel Institute for Immunology, Basel, Switzerland, 1998 Post-Doctoral Training, National Jewish Research Center, Denver, CO, 1992 PhD, Pharmacology and Toxicology, Medical College of Virginia/Virginia Commonwealth University, Richmond, VA, 1988 BS, Pharmacy, University of Toledo, Toledo, OH, 1983 Memberships Standing Member, NIH Innate Immunity and Inflammation (III) Study Section, 2013–2017 Member, American Association of Immunologists Member, American Association for the Advancement of Science Member, Society for Natural Immunity Member, American Association of Cancer Research Member, American Society of Hematology Chair, FCCC Facilities Parent Oversight Committee Member, FCCC Facility Advisory Committees Review Editor, Frontiers in NK and Innate Cell Biology, and Cancer Immunity and Immunotherapy Member, Cancer Immunotherapy Consortium (Cancer Research Institute)
Research Interest
Molecular mechanisms regulating the function of killer cell Ig-like receptors (KIR). Profiling the phenotype and function of NK cells in cancer patients. Therapeutic antibodies to target antitumor responses by human NK cells.
Publications
-
Pazina, T., Shemesh, A., Brusilovsky, M., Porgador, A., & Campbell, K. S. (2017). Regulation of the functions of natural cytotoxicity receptors by interactions with diverse ligands and alterations in splice variant expression. Frontiers in Immunology, 8.
-
Shemesh, A., Brusilovsky, M., Hadad, U., Teltsh, O., Edri, A., Rubin, E., ... & Porgador, A. (2016). Survival in acute myeloid leukemia is associated with NKp44 splice variants. Oncotarget, 7(22), 32933.
-
Davis, Z. B., Cogswell, A., Scott, H., Mertsching, A., Boucau, J., Wambua, D., ... & Barker, E. (2016). A conserved HIV-1-derived peptide presented by HLA-E renders infected T-cells highly susceptible to attack by NKG2A/CD94-bearing natural killer cells. PLoS pathogens, 12(2), e1005421.
-
Pazina, T., James, A. M., MacFarlane IV, A. W., Bezman, N. A., Henning, K. A., Bee, C., ... & Campbell, K. S. (2017). The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and–independent mechanisms. OncoImmunology, (just-accepted), 00-00.
-
MacFarlane IV, A. W., Jillab, M., Smith, M. R., Alpaugh, R. K., Cole, M. E., Litwin, S., ... & Campbell, K. S. (2017). NK Cell Dysfunction in Chronic Lymphocytic Leukemia is Associated with Loss of the Mature Cells Expressing Inhibitory Killer Cell Ig-like Receptors. OncoImmunology, (just-accepted), 00-00.
